Kalaris Therapeutics grants 220,000 options to CFO

Kalaris Therapeutics, Inc. reported an equity compensation grant to its Chief Financial Officer, Liisa Ann Bayko.

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. reported an equity compensation grant to its Chief Financial Officer, Liisa Ann Bayko. On July 20, 2026, she received a stock option to acquire 220,000 shares of common stock at an exercise price of $4.00 per share, expiring on July 19, 2036.

According to the vesting schedule, 25% of the underlying shares vest on July 20, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. Following this award, she holds options covering 220,000 shares.

Insider Trade Summary

Grant/Award: 220,000 shares

Grant/Award 1 txn

Insider Bayko Liisa Ann

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	220,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 220,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on July 20, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on July 20, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

Key Figures

Options Granted: 220,000 options Exercise Price: $4.00 per share Underlying Shares: 220,000 shares +3 more

6 metrics

Options Granted 220,000 options Stock Option (Right to Buy) granted to CFO on July 20, 2026

Exercise Price $4.00 per share Conversion or exercise price of the stock option

Underlying Shares 220,000 shares Common stock underlying the reported stock option

Expiration Date July 19, 2036 Expiration date of the stock option award

Initial Cliff Vesting 25% on July 20, 2027 First tranche of option vesting subject to continuous service

Post-transaction Holdings 220,000 options Total options held by the CFO after the reported grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title is listed as Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price is noted as the exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying the option are scheduled to vest over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"vesting is subject to continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kalaris Therapeutics (KLRS) disclose for its CFO?

Kalaris Therapeutics disclosed that CFO Liisa Ann Bayko received a grant of 220,000 stock options on July 20, 2026. These options are a compensation award, not an open-market share purchase or sale, and give her the right to buy common stock at a fixed price.

How many stock options did the Kalaris Therapeutics (KLRS) CFO receive and at what price?

The CFO of Kalaris Therapeutics received 220,000 stock options with an exercise price of $4.00 per share. This means she can later purchase up to 220,000 shares of common stock at $4.00 each, subject to the options’ vesting conditions.

What is the vesting schedule for the KLRS CFO’s 220,000 stock options?

The 220,000 options vest over four years. 25% of the underlying shares vest on July 20, 2027, and the remaining 75% vest in equal monthly installments thereafter, as long as the CFO maintains continuous service with the company.

When do the Kalaris Therapeutics (KLRS) CFO’s new stock options expire?

The CFO’s 220,000 stock options expire on July 19, 2036. After this expiration date, any unexercised options will lapse and no longer provide the right to buy Kalaris Therapeutics common stock at the $4.00 exercise price.

Did the Kalaris Therapeutics (KLRS) CFO buy or sell common shares in this Form 4?

No common share purchases or sales were reported. The Form 4 records a grant of stock options, classified as an acquisition of a derivative security. It is a compensation award rather than a market trade in Kalaris Therapeutics common stock.

How many options does the Kalaris Therapeutics (KLRS) CFO hold after this grant?

Following this reported transaction, the CFO holds options covering 220,000 shares of Kalaris Therapeutics common stock. This entire position reflects the newly granted option award reported in the Form 4 insider filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bayko Liisa Ann

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4	07/20/2026		A		220,000		(1)	07/19/2036	Common Stock	220,000	$0	220,000	D

Explanation of Responses:

1. The option was granted on July 20, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on July 20, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

	/s/ Andrew Oxtoby, Attorney-in-Fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)